Cyclophosphamid Cytoxan, Endoxan, Neosar
A drug being studied in colorectal cancer trials. It appears in 1 clinical trial.
What it is
Cyclophosphamide is an alkylating chemotherapy agent that serves as a lymphodepleting medication in adoptive cell therapy protocols for metastatic colorectal cancer. In CRC treatment, it is primarily used as part of conditioning regimens before tumor-infiltrating lymphocyte (TIL) therapy or engineered T-cell therapies targeting KRAS mutations. The drug creates an immunosuppressive environment that enhances the engraftment and expansion of infused therapeutic immune cells in patients with treatment-refractory metastatic disease.
How it works
Cyclophosphamide cross-links DNA strands through its active metabolites, phosphoramide mustard and acrolein, leading to cell death particularly in rapidly dividing cells. In the context of adoptive immunotherapy, it preferentially depletes regulatory T-cells and other immunosuppressive cells, creating space and reducing competition for homeostatic cytokines like IL-7 and IL-15 that support therapeutic T-cell expansion.
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Trials with this drug
1 recruitingGuides that may help
Written for patients and families, in plain language.